KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas

Histopathology

Volumn 61, Issue 6, 2012, Pages 1036-1042

  Alexander, Riley E ^a   Lopez Beltran, Antonio ^b   Montironi, Rodolfo ^c   MacLennan, Gregory T ^d   Post, Kristin M ^a   Bilbo, Sarah A ^a   Jones, Timothy D ^e   Huang, Wenbin ^f   Rao, Qiu ^g   Sen, Joyashree D ^a   Meehan, Kari ^a   Cornwell, Anita ^a   Miravalle, Leticia ^a   Cheng, Liang ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CÓRDOBA   (Spain)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Floyd Memorial Hospital and Health Services   (United States)

^f NANJING MEDICAL UNIVERSITY   (China)

^g MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Adenocarcinoma; Carcinogenesis; Differential diagnosis; KRAS mutation; Targeted therapy; Urinary bladder; Urothelial carcinoma with glandular differentiation

Indexed keywords

DNA; K RAS PROTEIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CLINICAL ARTICLE; COLON ADENOCARCINOMA; DISEASE COURSE; DISEASE SEVERITY; DNA EXTRACTION; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DNA, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; URINARY BLADDER NEOPLASMS;

EID: 84870362446     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04309.x     Document Type: Article

References (39)

1. Allegra CJ, Jessup JM, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 2009; 27; 2091-2096.
2. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008; 26; 1626-1234.
3. Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66; 3992-3995.
4. Barbacid M. Ras genes. Annu. Rev. Biochem. 1987; 56; 779-827.
5. Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim. Biophys. Acta 2002; 1602; 23-45.
6. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 2007; 7; 295-308.
7. Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 1982; 297; 474-478.
8. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res. 1989; 49; 4682-4689.
9. Ji Z, Mei FC, Xie J, Cheng X. Oncogenic KRAS activates hedgehog signaling pathway in pancreatic cancer cells. J. Biol. Chem. 2007; 282; 14048-14055.
10. Kang S, Kim HS, Seo SS, Park SY, Sidransky D, Dong SM. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma. Gynecol. Oncol. 2007; 105; 662-666.
11. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J. Urol. 2009; 27; 289-293.
12. Grignon DJ, Ro JY, Ayala AG, Johnson DE, Ordonez NG. Primary adenocarcinoma of the urinary bladder. A clinicopathologic analysis of 72 cases. Cancer 1991; 67; 2165-2172.
13. Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur. Urol. 2003; 44; 672-681.
14. Ploeg M, Aben KK, Hulsbergen-van de Kaa CA, Schoenberg MP, Witjes JA, Kiemeney LA. Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands cancer registry. J. Urol. 2010; 183; 915-920.
15. Suh N, Yang XJ, Tretiakova MS, Humphrey PA, Wang HL. Value of CDX2, villin, and alpha-methylacyl coenzyme A racemase immunostains in the distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma. Mod. Pathol. 2005; 18; 1217-1222.
16. Freeman DJ, Juan T, Reiner M et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin. Colorectal Cancer 2008; 7; 184-190.
17. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G. K-ras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br. J. Cancer 1994; 69; 367-371.
18. Keedy VL, Temin S, Somerfield MR et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 2011; 29; 2121-2127.
19. Barton S, Starling N, Swanton C. Predictive molecular markers of response to epidermal growth factor receptor (EGFR) family-targeted therapies. Curr. Cancer Drug Targets 2010; 10; 799-812.
20. Jonker DJ, O'Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med. 2007; 357; 2040-2048.
21. Sobrero AF, Maurel J, Fehrenbacher L et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008; 26; 2311-2319.
22. Cheng L, Alexander RE, MacLennan GT et al. Molecular pathology of lung cancer: key to personalized medicine. Mod. Pathol. 2012; 25; 347-369.
23. Schimanski CC, Linnemann U, Berger MR. Sensitive detection of K-ras mutations augments diagnosis of colorectal cancer metastases in the liver. Cancer Res. 1999; 59; 5169-5175.
24. De Roock W, Biesmans B, De Schutter J, Tejpar S. Clinical biomarkers in oncology: focus on colorectal cancer. Mol. Diagn. Ther. 2009; 13; 103-114.
25. Wang HL, Lopategui J, Amin MB, Patterson SD. KRAS mutation testing in human cancers: the pathologist's role in the era of personalized medicine. Adv. Anat. Pathol. 2010; 17; 23-32.
26. Jackman DM, Miller VA, Cioffredi LA et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin. Cancer Res. 2009; 15; 5267-5273.
27. Losi L, Baisse B, Bouzourene H, Benhattar J. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 2005; 26; 916-922.
28. Thunnissen FB, Prinsen C, Hol B et al. Smoking history and lung carcinoma: KRAS mutation is an early hit in lung adenocarcinoma development. Lung Cancer 2012; 75; 156-160.
29. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br. J. Cancer 2001; 85; 692-696.
30. Bouzourene H, Gervaz P, Cerottini JP et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur. J. Cancer 2000; 36; 1008-1015.
31. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 2010; 5; e13821.
32. Kapur P, Lotan Y, King E et al. Primary adenocarcinoma of the urinary bladder: value of cell cycle biomarkers. Am. J. Clin. Pathol. 2011; 135; 822-830.
33. Zaghloul MS, Nouh A, Nazmy M et al. Long-term results of primary adenocarcinoma of the urinary bladder: a report on 192 patients. Urol. Oncol. 2006; 24; 13-20.
34. Del Sordo R, Bellezza G, Colella R, Mameli MG, Sidoni A, Cavaliere A. Primary signet-ring cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 5 cases. Appl. Immunohistochem. Mol. Morphol. 2009; 17; 18-22.
35. Kunze E, Krassenkova I, Fayyazi A. Tumor-associated neoexpression of the pS2 peptide and MUC5AC mucin in primary adenocarcinomas and signet ring cell carcinomas of the urinary bladder. Histol. Histopathol. 2008; 23; 539-548.
36. Wright JL, Porter MP, Li CI, Lange PH, Lin DW. Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder. Cancer 2006; 107; 721-728.
37. Karimianpour N, Mousavi-Shafaei P, Ziaee AA et al. Mutations of RAS gene family in specimens of bladder cancer. Urol. J. 2008; 5; 237-242.
38. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 2010; 16; 790-799.
39. Black PC, Agarwal PK, Dinney CP. Targeted therapies in bladder cancer - an update. Urol. Oncol. 2007; 25; 433-438.